ロード中...
PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Paediatrician Publishers, LLC
2012-08-01
|
| シリーズ: | Pediatričeskaâ Farmakologiâ |
| 主題: | |
| オンライン･アクセス: | https://www.pedpharma.ru/jour/article/view/302 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|